Global Scleroderma Therapeutics Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI12240665

Publication Date:

December 16, 2024

Pages:

124

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Scleroderma Therapeutics market size was valued at US$ 1371.8 million in 2023. With growing demand in downstream market, the Scleroderma Therapeutics is forecast to a readjusted size of US$ 1748.5 million by 2030 with a CAGR of 3.5% during review period.
The research report highlights the growth potential of the global Scleroderma Therapeutics market. Scleroderma Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Scleroderma Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Scleroderma Therapeutics market.
Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Scleroderma Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Scleroderma Therapeutics market. It may include historical data, market segmentation by Type (e.g., Immunosuppressors, Phosphodiesterase 5 Inhibitors - PHA), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Scleroderma Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Scleroderma Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Scleroderma Therapeutics industry. This include advancements in Scleroderma Therapeutics technology, Scleroderma Therapeutics new entrants, Scleroderma Therapeutics new investment, and other innovations that are shaping the future of Scleroderma Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Scleroderma Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Scleroderma Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Scleroderma Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Scleroderma Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Scleroderma Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Scleroderma Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Scleroderma Therapeutics market.
Market Segmentation:
Scleroderma Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Immunosuppressors
Phosphodiesterase 5 Inhibitors - PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Analgesics
Others
Segmentation by application
Systemic
Localized
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Scleroderma Therapeutics Market Size 2019-2030
2.1.2 Scleroderma Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Scleroderma Therapeutics Segment by Type
2.2.1 Immunosuppressors
2.2.2 Phosphodiesterase 5 Inhibitors - PHA
2.2.3 Endothelin Receptor Antagonists
2.2.4 Prostacyclin Analogues
2.2.5 Calcium Channel Blockers
2.2.6 Analgesics
2.2.7 Others
2.3 Scleroderma Therapeutics Market Size by Type
2.3.1 Scleroderma Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Scleroderma Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Scleroderma Therapeutics Segment by Application
2.4.1 Systemic
2.4.2 Localized
2.5 Scleroderma Therapeutics Market Size by Application
2.5.1 Scleroderma Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Scleroderma Therapeutics Market Size Market Share by Application (2019-2024)
3 Scleroderma Therapeutics Market Size by Player
3.1 Scleroderma Therapeutics Market Size Market Share by Players
3.1.1 Global Scleroderma Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Scleroderma Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Scleroderma Therapeutics by Regions
4.1 Scleroderma Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Scleroderma Therapeutics Market Size Growth (2019-2024)
4.3 APAC Scleroderma Therapeutics Market Size Growth (2019-2024)
4.4 Europe Scleroderma Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Scleroderma Therapeutics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Scleroderma Therapeutics Market Size by Country (2019-2024)
5.2 Americas Scleroderma Therapeutics Market Size by Type (2019-2024)
5.3 Americas Scleroderma Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Scleroderma Therapeutics Market Size by Region (2019-2024)
6.2 APAC Scleroderma Therapeutics Market Size by Type (2019-2024)
6.3 APAC Scleroderma Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Scleroderma Therapeutics by Country (2019-2024)
7.2 Europe Scleroderma Therapeutics Market Size by Type (2019-2024)
7.3 Europe Scleroderma Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Scleroderma Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Scleroderma Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Scleroderma Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Scleroderma Therapeutics Market Forecast
10.1 Global Scleroderma Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Scleroderma Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Scleroderma Therapeutics Forecast
10.1.3 APAC Scleroderma Therapeutics Forecast
10.1.4 Europe Scleroderma Therapeutics Forecast
10.1.5 Middle East & Africa Scleroderma Therapeutics Forecast
10.2 Americas Scleroderma Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Scleroderma Therapeutics Market Forecast
10.2.2 Canada Scleroderma Therapeutics Market Forecast
10.2.3 Mexico Scleroderma Therapeutics Market Forecast
10.2.4 Brazil Scleroderma Therapeutics Market Forecast
10.3 APAC Scleroderma Therapeutics Forecast by Region (2025-2030)
10.3.1 China Scleroderma Therapeutics Market Forecast
10.3.2 Japan Scleroderma Therapeutics Market Forecast
10.3.3 Korea Scleroderma Therapeutics Market Forecast
10.3.4 Southeast Asia Scleroderma Therapeutics Market Forecast
10.3.5 India Scleroderma Therapeutics Market Forecast
10.3.6 Australia Scleroderma Therapeutics Market Forecast
10.4 Europe Scleroderma Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Scleroderma Therapeutics Market Forecast
10.4.2 France Scleroderma Therapeutics Market Forecast
10.4.3 UK Scleroderma Therapeutics Market Forecast
10.4.4 Italy Scleroderma Therapeutics Market Forecast
10.4.5 Russia Scleroderma Therapeutics Market Forecast
10.5 Middle East & Africa Scleroderma Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Scleroderma Therapeutics Market Forecast
10.5.2 South Africa Scleroderma Therapeutics Market Forecast
10.5.3 Israel Scleroderma Therapeutics Market Forecast
10.5.4 Turkey Scleroderma Therapeutics Market Forecast
10.5.5 GCC Countries Scleroderma Therapeutics Market Forecast
10.6 Global Scleroderma Therapeutics Forecast by Type (2025-2030)
10.7 Global Scleroderma Therapeutics Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 F. Hoffmann-La Roche AG
11.1.1 F. Hoffmann-La Roche AG Company Information
11.1.2 F. Hoffmann-La Roche AG Scleroderma Therapeutics Product Offered
11.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 F. Hoffmann-La Roche AG Main Business Overview
11.1.5 F. Hoffmann-La Roche AG Latest Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Information
11.2.2 Bristol-Myers Squibb Company Scleroderma Therapeutics Product Offered
11.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Bristol-Myers Squibb Company Main Business Overview
11.2.5 Bristol-Myers Squibb Company Latest Developments
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Information
11.3.2 Celgene Corporation Scleroderma Therapeutics Product Offered
11.3.3 Celgene Corporation Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Celgene Corporation Main Business Overview
11.3.5 Celgene Corporation Latest Developments
11.4 Argentis Pharmaceuticals, LLC
11.4.1 Argentis Pharmaceuticals, LLC Company Information
11.4.2 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Product Offered
11.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Argentis Pharmaceuticals, LLC Main Business Overview
11.4.5 Argentis Pharmaceuticals, LLC Latest Developments
11.5 Bayer AG
11.5.1 Bayer AG Company Information
11.5.2 Bayer AG Scleroderma Therapeutics Product Offered
11.5.3 Bayer AG Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Bayer AG Main Business Overview
11.5.5 Bayer AG Latest Developments
11.6 Boehringer Ingelheim International GmbH
11.6.1 Boehringer Ingelheim International GmbH Company Information
11.6.2 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Product Offered
11.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Boehringer Ingelheim International GmbH Main Business Overview
11.6.5 Boehringer Ingelheim International GmbH Latest Developments
11.7 Akashi Therapeutics
11.7.1 Akashi Therapeutics Company Information
11.7.2 Akashi Therapeutics Scleroderma Therapeutics Product Offered
11.7.3 Akashi Therapeutics Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Akashi Therapeutics Main Business Overview
11.7.5 Akashi Therapeutics Latest Developments
11.8 Prometic Life Sciences, Inc.
11.8.1 Prometic Life Sciences, Inc. Company Information
11.8.2 Prometic Life Sciences, Inc. Scleroderma Therapeutics Product Offered
11.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Prometic Life Sciences, Inc. Main Business Overview
11.8.5 Prometic Life Sciences, Inc. Latest Developments
11.9 Emerald Health Pharmaceuticals
11.9.1 Emerald Health Pharmaceuticals Company Information
11.9.2 Emerald Health Pharmaceuticals Scleroderma Therapeutics Product Offered
11.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Emerald Health Pharmaceuticals Main Business Overview
11.9.5 Emerald Health Pharmaceuticals Latest Developments
11.10 Kadmon Holdings, Inc.
11.10.1 Kadmon Holdings, Inc. Company Information
11.10.2 Kadmon Holdings, Inc. Scleroderma Therapeutics Product Offered
11.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Kadmon Holdings, Inc. Main Business Overview
11.10.5 Kadmon Holdings, Inc. Latest Developments
11.11 Seattle Genetics, Inc.
11.11.1 Seattle Genetics, Inc. Company Information
11.11.2 Seattle Genetics, Inc. Scleroderma Therapeutics Product Offered
11.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Seattle Genetics, Inc. Main Business Overview
11.11.5 Seattle Genetics, Inc. Latest Developments
11.12 Cytori Therapeutics, Inc.
11.12.1 Cytori Therapeutics, Inc. Company Information
11.12.2 Cytori Therapeutics, Inc. Scleroderma Therapeutics Product Offered
11.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Cytori Therapeutics, Inc. Main Business Overview
11.12.5 Cytori Therapeutics, Inc. Latest Developments
11.13 Fibrocell Science, Inc.
11.13.1 Fibrocell Science, Inc. Company Information
11.13.2 Fibrocell Science, Inc. Scleroderma Therapeutics Product Offered
11.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Fibrocell Science, Inc. Main Business Overview
11.13.5 Fibrocell Science, Inc. Latest Developments
11.14 Chemomab
11.14.1 Chemomab Company Information
11.14.2 Chemomab Scleroderma Therapeutics Product Offered
11.14.3 Chemomab Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Chemomab Main Business Overview
11.14.5 Chemomab Latest Developments
11.15 Corbus Pharmaceuticals Holdings, Inc.
11.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Information
11.15.2 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Product Offered
11.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Corbus Pharmaceuticals Holdings, Inc. Main Business Overview
11.15.5 Corbus Pharmaceuticals Holdings, Inc. Latest Developments
11.16 Genkyotex
11.16.1 Genkyotex Company Information
11.16.2 Genkyotex Scleroderma Therapeutics Product Offered
11.16.3 Genkyotex Scleroderma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Genkyotex Main Business Overview
11.16.5 Genkyotex Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂